Valdez, B.C.; Tsimberidou, A.M.; Yuan, B.; Baysal, M.A.; Chakraborty, A.; Andersen, C.R.; Andersson, B.S.
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. Int. J. Mol. Sci. 2024, 25, 9241.
https://doi.org/10.3390/ijms25179241
AMA Style
Valdez BC, Tsimberidou AM, Yuan B, Baysal MA, Chakraborty A, Andersen CR, Andersson BS.
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. International Journal of Molecular Sciences. 2024; 25(17):9241.
https://doi.org/10.3390/ijms25179241
Chicago/Turabian Style
Valdez, Benigno C., Apostolia M. Tsimberidou, Bin Yuan, Mehmet A. Baysal, Abhijit Chakraborty, Clark R. Andersen, and Borje S. Andersson.
2024. "Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations" International Journal of Molecular Sciences 25, no. 17: 9241.
https://doi.org/10.3390/ijms25179241
APA Style
Valdez, B. C., Tsimberidou, A. M., Yuan, B., Baysal, M. A., Chakraborty, A., Andersen, C. R., & Andersson, B. S.
(2024). Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. International Journal of Molecular Sciences, 25(17), 9241.
https://doi.org/10.3390/ijms25179241
